

# The “PepSAVI-MS” Pipeline for Natural Product Bioactive Peptide Discovery

Christine L. Kirkpatrick,<sup>†</sup> Christopher A. Broberg,<sup>†</sup> Elijah N. McCool,<sup>†</sup> Woo Jean Lee,<sup>†</sup> Alex Chao,<sup>†</sup> Evan W. McConnell,<sup>†</sup> David A. Pritchard,<sup>‡</sup> Michael Hebert,<sup>†</sup> Renee Fleeman,<sup>||</sup> Jessie Adams,<sup>||</sup> Amer Jamil,<sup>⊥</sup> Laurence Madera,<sup>#</sup> Adam A. Strömstedt,<sup>▽</sup> Ulf Göransson,<sup>▽</sup> Yufeng Liu,<sup>§</sup> David W. Hoskin,<sup>#</sup> Lindsey N. Shaw,<sup>||</sup> and Leslie M. Hicks\*,<sup>†</sup>

<sup>†</sup>Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

<sup>‡</sup>Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

<sup>§</sup>Department of Statistics and Operations Research, Department of Genetics, Department of Biostatistics, and Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

<sup>||</sup>Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida, Tampa, Florida, United States


<sup>⊥</sup>Department of Biochemistry, University of Agriculture Faisalabad, Faisalabad, Pakistan

<sup>#</sup>Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada

<sup>▽</sup>Division of Pharmacognosy, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden

## S Supporting Information

**ABSTRACT:** The recent increase in extensively drug-resistant bacterial pathogens and the associated increase of morbidity and mortality demonstrate the immediate need for new antibiotic backbones with novel mechanisms of action. Here, we report the development of the PepSAVI-MS pipeline for bioactive peptide discovery. This highly versatile platform employs mass spectrometry and statistics to identify bioactive peptide targets from complex biological samples. We validate the use of this platform through the successful identification of known bioactive peptides from a botanical species, *Viola odorata*. Using this pipeline, we have widened the known antimicrobial spectrum for *V. odorata* cyclotides, including antibacterial activity of cycloviolacin O2 against *A. baumannii*. We further demonstrate the broad applicability of the platform through the identification of novel anticancer activities for cycloviolacins by their cytotoxicity against ovarian, breast, and prostate cancer cell lines.



Difficult-to-treat nosocomial and community acquired fungal and extensively drug-resistant bacterial infections are increasingly commonplace, new viral diseases are emerging and spreading rapidly, and cancer remains a leading cause of death worldwide. In the United States, there are almost two million hospital-acquired bacterial infections each year, resulting in ~100 000 deaths.<sup>1</sup> The emergence of ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) pathogens has led to a significant increase in multidrug-resistant (MDR) infections in the clinic with associated increases in morbidity and mortality.<sup>2</sup> In addition, the recent emergence, resurgence, and spread of viruses, including Zika, SARS, West Nile, Ebola, and MERS,<sup>3</sup> for which there are limited or no direct-acting antivirals, highlight the susceptibility of the human population to future potentially untreatable pandemics. Furthermore, despite continued progress in anticancer therapeutics, limitations to current lead compounds of nonspecific toxicity, poor drug penetration, and

multidrug resistance have emphasized the need for discovery of anticancer therapeutics with novel mechanisms of action.<sup>4</sup> With many bacteria now unresponsive to multiple classes of antimicrobial compounds and cancer being the leading cause of death worldwide, there is an undeniable and desperate need to identify novel pharmacological chemistries and accelerate their development through new methods and innovative technologies.

Natural products have long been sources of virtually all traditional medicinal preparations and have been the single most successful source of lead compounds for drug discovery.<sup>5</sup> Specifically, plants have played a significant role in the treatment of human ailments since prehistoric times. The teas and tinctures of times past are one source of drug discovery, allowing the ethnobotanically guided isolation and character-

**Received:** September 13, 2016

**Accepted:** December 19, 2016

**Published:** December 19, 2016



ization of pharmacologically active compounds for the treatment of bacterial and fungal infections, cancers, and other ailments. Despite historical relevance and past success, challenges associated with natural product discovery have slowed progress in drug discovery efforts. In addition, natural product discovery efforts have largely focused on small molecule constituents. However, recent discoveries have revealed ribosomally synthesized, post-translationally modified peptide natural products (RiPPs) with substantial structural diversity and bioactivity potential, including novel mechanisms of action.<sup>6,7</sup> While traditionally studied for antifungal and antibacterial properties, recent studies have piqued interest in these peptides as potential anticancer therapeutics.<sup>8</sup> Peptides offer several advantages over other small and large molecule drug candidates—including greater efficacy, selectivity, and specificity, relative to small organic molecules, better tissue penetration, and reduced immunogenicity and manufacturing costs, relative to proteins/antibodies. Advances in peptide modification, formulation, and delivery methods can address known limitations of peptidic drug candidates,<sup>9</sup> including modification of peptide length/content to increase selectivity,<sup>10</sup> stapling, and/or peptidomimetic conversion techniques to improve pharmacokinetic properties,<sup>11</sup> as well as encapsulation methods to protect from proteolytic degradation.<sup>10</sup> However, RiPPs fall outside the scope of standard therapeutic screening approaches and elude detection via standard -omic workflows, because of their large size, structural diversity, and high level of post-translational modification; therefore, systematic approaches for discovery and characterization are in nascent development.<sup>12</sup> Developing natural product screens for antimicrobially active RiPPs (AMPs) has the potential for discovery of new bioactive compounds with novel mechanisms of action able to address the growing problem of antimicrobial resistance.

Current methods for RiPP discovery often rely on bioassay-guided fractionation<sup>13</sup> or genomic mapping<sup>12,14,15</sup> (e.g., Pep2 Path, RiPPquest) to facilitate downstream analysis. Relying on iterative rounds of chromatographic separations, bioassay-guided fractionation is extremely time-consuming and provides no structural information until late in the discovery process. In addition, this approach often leads to replication of previously known compounds, as a bias toward highly abundant and highly active compounds is evident. While alternative genomic mapping approaches can provide structural information from the beginning, prior genomic sequencing and knowledge of peptide biosynthetic pathways is required. Furthermore, this approach is unable to provide direct bioactivity information on the target peptide, thus necessitating downstream isolation and activity screening to determine function and biological activity. Recent approaches to address some of these limitations have been proposed<sup>16</sup> (e.g., compound activity mapping); however, these platforms are specific to small molecule identification and do not translate efficiently toward advancing untargeted proteomics approaches.

To this end, we have developed the PepSAVI-MS (Statistically guided bioactive peptides prioritized via mass spectrometry) pipeline for the screening and identification of cationic bioactive peptides from natural product sources. For streamlined identification of bioactive peptides, our platform employs only one round of crude fractionation and relies on the power of mass spectrometry and statistics to assign bioactivity to individual components. Furthermore, we implement physiologically relevant whole cell bioassays to obtain activity

information early in the discovery process, thus focusing on only active peptide targets. Our PepSAVI-MS pipeline is adaptable to any natural product source of peptides and can test against multiple physiological targets of various cell lines or organisms, including bacteria, fungi, viruses, protozoans, and cancer cells. Herein, we demonstrate the PepSAVI-MS pipeline using plant material and focusing on peptides with antimicrobial and/or anticancer properties. Proof-of-principle studies for a known AMP from the plant *Viola odorata* are presented to validate this workflow. In addition, we use this pipeline to explore novel antibacterial and anticancer activities of the *Viola odorata* cyclotide, cycloviolacin O2.

## ■ EXPERIMENTAL SECTION

**Source Materials and Growth Conditions.** *Viola odorata* seedlings purchased from Strictly Medicinal Seeds (formerly Horizon Herbs, Williams, OR) were grown to mature rosette stage (~6 weeks) under standard greenhouse conditions. Seedlings were planted in nutrient-rich soil under controlled temperature (63.5–68.5 °F) and light cycle conditions (14 h of light). Aerial tissue was harvested with immediate flash freezing under liquid nitrogen and stored at –80 °C until subsequent extraction.

**Creation of Peptide Libraries.** *Extraction.* Frozen tissue (100 g) was ground under liquid nitrogen using a mortar and pestle and aqueous extracted in 300 mL of 10% acetic acid with protease inhibitors (Roche, 1 tablet/50 mL) and stirring for 4 h at 4 °C. Insoluble material was pelleted by centrifugation at 13 000 rcf for 45 min, and 0.45  $\mu$ m stericup filtration (Millipore) was used to remove remaining particulates. Protein concentration filters (MWCO 30 kDa; Millipore) were used to remove high-molecular-weight species, and subsequent dialysis (0.1–1 kDa cutoff; SpectrumLabs) into 5 mM ammonium formate pH 2.7 was performed to eliminate small-molecule contaminants. The sample was concentrated via vacuum centrifugation to 4 mL to generate the final crude extract.

**HPLC Fractionation.** Extracts were subjected to a 47 min SCX method, using a PolySulphethyl A column (100 mm  $\times$  4.6 mm, 3  $\mu$ m particles, PolyLC). A salt gradient (Figure S-1 in the Supporting Information) was employed using a linear ramp from 5 mM ammonium formate, 20% acetonitrile, pH 2.7 to 500 mM ammonium formate, 20% acetonitrile, pH 3.0. Fractions were collected across the 47 min run in one-min intervals and desalted with three washes of 1.3 mL water using a vacuum concentrator. Peptide libraries were stored in water (400  $\mu$ L/fraction) at 4 °C until bioactivity assay.

**Bioactivity Screening.** *Bacterial.* *Escherichia coli* 25922 was obtained through ATCC and the ESKAPE pathogen strains are clinical isolates that belong to a collection acquired by the Shaw Lab [recall that ESKAPE consists of *Enterococcus faecium* (1449), *Staphylococcus aureus* (635), *Klebsiella pneumoniae* (1433), *Acinetobacter baumannii* (1403), *Pseudomonas aeruginosa* (1423), *Enterobacter cloacae* (1454)].<sup>17</sup> Bacterial cultures were synchronized to mid-logarithmic phase by inoculating 1 mL of overnight culture into 100 mL of TSB and incubated for 3 h, shaking at 37 °C. All assays were performed in 96-well microtiter plates by adding 10  $\mu$ L of 2 $\times$  MH broth, 20  $\mu$ L of 1 $\times$  MH broth, 10  $\mu$ L of peptide fraction, and 10  $\mu$ L of 0.5 OD<sub>600</sub> bacteria culture. The addition of 2 $\times$  broth ensured sufficient nutrients were available since the peptide fractions, in water, accounted for one-fifth of the final volume. TSB was used to test *S. aureus*, because of its decreased growth rate in MHB. Ampicillin (100  $\mu$ g/mL) or tetracycline (100  $\mu$ g/mL) was

added respectively to *E. coli* or ESKAPE pathogen plates in place of the plant fraction to serve as the positive control, and water as the negative control. The prepared plates were incubated at 37 °C, 275 rpm shaking for 1.5–4 h, depending on the growth characteristic of the organism before 5  $\mu$ L of the cell viability indicator dye, resazurin (1.19 mM), was added to each well. After one additional hour of shaking and incubation, a fluorescence read of 544 nm (ex) and 590 nm (em) was collected to measure relative fluorescence units (RFU) for each sample. Percent activity of each well was calculated using the formula

$$\% \text{ activity} = \left[ 1 - \left( \frac{\text{RFU of fraction} - \text{RFU of positive control}}{\text{RFU of negative control} - \text{RFU of positive control}} \right) \right] \times 100$$

**Cancer Cell Lines. Cell Viability Assay.** MDA-MB-231 breast cancer cells, OVCAR ovarian cancer cells, PC3 prostate cancer cells, or human dermal fibroblasts in the appropriate growth medium were plated into 96-well flat-bottom microtiter plates at  $2 \times 10^4$  cells/well and cultured for 24 h in a 37 °C humidified incubator in order to form adherent monolayers. The medium was then removed and replaced with a fresh serum-free medium with or without individual plant fractions to be assayed for cytotoxic activity. Cells were then cultured for an additional 24 h. Two hours before the end of the culture, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution was added to each well at a final concentration of 0.5 mg/mL to measure mitochondrial succinate dehydrogenase activity. Culture supernatants were discarded and formazan crystals were solubilized in 0.1 mL of dimethyl sulfoxide. Absorbance was measured at 570 nm on an ASYS Expert 96 plate-reader (Montreal Biotech, Inc., Kirkland, QC, Canada). Absorbance in each treatment group was compared to the control to determine percent reduction in viability, as reflected by the change in mitochondrial succinate dehydrogenase activity.

**LC-MS/MS.** Peptide libraries were analyzed via a nano-LC-ESI-MS/MS platform: nanoAcquity (Waters, Milford, MA) coupled to a TripleTOF5600 (AB Sciex, Framingham, MA). Peptide fractions were diluted to the appropriate loading level, acidified with formic acid and transferred to low-volume 96-well plates covered with adhesive plate seals. Each sample was injected onto a trap column (NanoAcquity UPLC 2G-W/M Trap 5  $\mu$ m Symmetry C18, 180  $\mu$ m  $\times$  20 mm; Waters) before subsequent passing onto the analytical C18 column (10k PSI, 100 Å, 1.8  $\mu$ m, 75  $\mu$ m  $\times$  250 mm; Waters). Peptide separation was carried out at a flow rate of 0.3  $\mu$ L/min using a linear ramp of 5%–50% B (mobile phase A, 1% formic acid; mobile phase B, 1% formic acid in acetonitrile) over 30 min. The MS was operated in positive-ion, high-sensitivity mode with the MS survey spectrum using a mass range of 350–1600 Da in 250 ms and information-dependent acquisition (IDA) of MS/MS data. The first 20 features above 150 counts threshold and having a charge state of +2 to +5 were fragmented using rolling collision energy ( $\pm 5\%$ ). Auto calibration was performed every eight samples (8 h). The data have been deposited to the ProteomeXchange Consortium via the PRIDE<sup>18</sup> partner repository with the dataset identifier PXD004780. Deisotoped peak lists for each fraction were generated using Progenesis Q1 for Proteomics software (Nonlinear Dynamics, v.2.0). To align runs, a reference run was chosen from a subset of bioactive fractions (15–30 for *V. odorata*). Automatic processing settings

with a retention time filter of 14–45 min were used to align and peak pick ions across all runs. Identified features were quantified using AUC integration of survey scan data based on the summed intensity of each deisotoped feature. Data was exported as “peptide ion data” with the default parameters from Progenesis at the “Identify Peptides” stage in the software. Our analysis yielded 6258 unique MS features for *V. odorata*.

**Data Reduction and Statistical Modeling.** Areas of interest in the bioactivity profile were selected for subsequent data reduction and modeling. The bioactivity region for each *V. odorata* dataset was defined for each pathogen based on the observed bioactivity profile as follows: ovarian cancer (18–22), breast cancer (18–22), prostate cancer (18–22), *A. baumannii* (17–21), *P. aeruginosa* (18–21), *E. coli* (18–25), and *F. graminearum* (19–24). Using the PepSAVI-MS software, background ions were eliminated through retention time, mass, and charge-state filters to reduce the data to potential compounds of interest. Peak-picked data believed to belong to the same MS feature were binned together if their *m/z* values were within a 0.05 Da window and their charge states were identical. Next, workflow-informed filtering criteria were applied using the following rules: (1) *m/z* intensity maximum must fall inside the range of the bioactivity “area of interest”, (2) the *m/z* intensity of species meeting the first criteria must be <1% of its respective maximum peak intensity in the areas bordering said “area of interest”, (3) there must be nonzero abundance in the fraction following the maximum intensity fraction, (4) the maximum intensity must be >1000 in active window, and (5) all charge states greater than +10 are excluded. All *m/z* species meeting these filtering criteria were modeled using the elastic net estimator with a quadratic penalty parameter specification of 0.001 to determine each species’ contribution to the observed overall bioactivity profile. The resulting list contains candidate compounds ranked in order of when they entered the model, such that the highest ranked compounds have the greatest likelihood to be contributing to the bioactivity.


**Isolation of cyO2.** Dried aerial plant material from *Viola odorata* (Alfred Galke GmbH, Bad Grund, DE) was used to isolate cyO2. Cyclotide isolation was carried out according to Herrmann et al. with minor modifications.<sup>19</sup> Briefly, ground plant material was subjected to extraction with 60% methanol in water, followed by filtration and liquid–liquid extraction with dichloromethane. The polar phase was diluted and acidified before subjected to a strong cation exchange chromatography to capture cyclotides of net positive charge. Individual cyclotides, i.e. cyO2, were then isolated using RP-HPLC. Final cyO2 was of >95% purity assessed by RP-HPLC (214 nm).

**Validation of cyO2 Activity.** Minimum inhibitory concentration determination of cyO2 against *E. coli* and *A. baumannii* was performed in Mueller–Hinton media, using a broth microdilution method. Bacteria were grown overnight and added to the assay at  $10^5$  CFU/mL and turbidity/clearing was observed after 20 h incubation. Assay was performed in triplicate starting with 10 or 25  $\mu$ M cyO2 for *E. coli* or *A. baumannii*, respectively, and using 2 $\times$  serial dilution. Mean MICs of 5 and 15  $\mu$ M were obtained for each species, respectively. The mean IC<sub>50</sub> value of 6.6  $\mu$ g/mL for cyO2 against the PC3 prostate cancer cell line was determined using duplicate measurements of the MTT cell viability assay, as described above.



## RESULTS AND DISCUSSION

**Overview.** Relying on a multipronged approach, the PepSAVI-MS pipeline utilizes selective extraction and fractionation of peptide source material, bioactivity screening, and statistics-guided mass spectrometry-based peptidomics for the targeted identification and characterization of only putative bioactive compounds (Figure 1). We demonstrate use of the



**Figure 1.** Overall workflow for the PRISMS screening platform including (a) creation of peptide libraries through extraction and fractionation of crude extracts, (b) whole-cell bioactivity screening of peptide libraries against pathogen targets of interest, (c) LC-MS/MS analysis of active peptide libraries, and (d) statistical modeling of LC-MS/MS datasets vs active bioactivity regions for determination of (e) putative bioactive peptide targets.

PepSAVI-MS pipeline focusing on bioactive peptides from the plant kingdom and their activity against a panel of microbial pathogens and cancer cell lines.

**Plant Selection, Cultivation, and Harvesting.** Plant species are selected based on several criteria, including known bioactivity of the plant, traditional use, and availability. While many plants are commonly used for their perceived health-related benefits, the bioactive peptides from these species have not been comprehensively evaluated. Seeds/seedlings of selected species are obtained through commercial sources and grown in a laboratory greenhouse. Tissue is harvested with immediate flash freezing in liquid nitrogen for future extraction.

**Peptide Library Creation.** (Figure 1a). Preparation of crude extracts from plant material includes aqueous extraction and size exclusion to selectively target AMP-like molecules, i.e., water-soluble compounds that are smaller than 10 kDa.<sup>20,21</sup> Extracts are crudely fractionated using strong cation exchange (SCX) chromatography such that individual peptides elute over multiple sequential fractions. The distribution of bioactive peptide abundance across sequential fractions is reflected in the distribution of activity seen in bioactivity data for the same fractions. As peptides are eluted using volatile salts during SCX, peptide libraries are simply desalted via vacuum concentration for compatibility with downstream bioassays. Peptide libraries can be created from constitutive expression, as well as from abiotic and biotic stresses known to induce the production of defense compounds.<sup>22–25</sup>

**Bioactivity Screening.** Peptide libraries are assayed for growth inhibition against pathogens of interest using physiologically relevant whole-cell bioactivity screens (Figure

1b). Library fractions are incubated with a microbial or cancer cell culture and the presence of bioactive peptides in a given fraction will result in inhibition of culture growth during the incubation period. For bacterial assays, the remaining viable cells are quantified indirectly by spectrophotometric measurement of the irreversible intracellular reduction of resazurin.<sup>26</sup> For anticancer bioactivity, cytotoxicity assays are performed using MTT-based assays to measure mitochondrial succinate dehydrogenase activity with absorbance measurements at 570 nm. Values for each fraction are compared to positive and negative controls containing a known therapeutic or water, respectively, to determine a percent activity of each library fraction, where a small value of remaining viable cells indicates high activity. Species with bioactivity profiles of interest are prioritized for LC-MS/MS and downstream statistical analysis.


**MS Profiling, Data Reduction, and Statistical Modeling to Identify Putative Bioactive Peptides.** Peptide libraries are analyzed via nanoLC-ESI-MS/MS to obtain accurate intact mass and relative intensity information for peptide constituents contained within each library fraction (Figure 1c). The resulting data array is processed using the developed PepSAVI-MS software package. Using this function, unwanted compounds can be eliminated using mass, charge, and retention time filters. Remaining compounds are binned to condense all of the hits for a given  $m/z$  ratio into a single feature. Binned datasets are then filtered using the following workflow-informed criteria to narrow the library to those peptides most likely contributing to the bioactivity profile: (1)  $m/z$  intensity maximum must fall inside the range of the bioactivity “area of interest”, (2) the  $m/z$  intensity of species meeting the first criteria must be <1% of its respective maximum peak intensity in the areas bordering said “area of interest”, (3) there must be nonzero abundance in fraction following the maximum intensity fraction, (4) the maximum abundance must be >1000 in active window, and (5) all charge states greater than +10 are excluded. This filtering results in a reduction of each dataset to those peptides with their highest abundance in the bioactive region. Subsequently, sparse penalized linear regression modeling (elastic net,<sup>27,28</sup> including lasso<sup>29</sup>) is applied to correlate the relative abundance of post-filtered peptides and percent activity across library fractions in order to identify the specific peptide(s) causing bioactivity (Figure 1d). Because multiple peptides could jointly contribute to the bioactivity across a group of active fractions, a simple marginal correlation analysis strategy may produce inaccurate or spurious results for any individually contributing peptide. However, sparse penalized linear regression is able to account for this co-contribution to activity and results in more-accurate identification of putative bioactive peptide species under the theoretical model. Elastic net regularization is an appropriate penalization specification, because it elicits a sparse set of peptides contributing to bioactivity levels, helping to identify peptides most likely responsible for the corresponding bioactivities without strict limitation to a set number of peptides being selected. Identification of such a set facilitates prioritization of peptides for subsequent characterization and validation (Figure 1e). The elastic net path for fixed choice of quadratic penalty parameter can be obtained through a transformation of the predictor data and a subsequent application of the LARS algorithm.<sup>30</sup> Thus, in order to obtain a list of candidate compounds most likely to be contributing to the bioactivity, the order in which the coefficients of the compounds first obtain a nonzero value is tracked along the

course of the algorithm, with coefficients that become nonzero earlier presumed to be better candidates for further investigation.

**Peptide Characterization.** Prioritized peptides are characterized via appropriate strategies, depending on the target(s) of interest. While a top-down approach<sup>31</sup> is used for detection of peptides of interest and may be sufficient for characterization, a hybrid approach of chemical or enzymatic reaction followed by LC-MS/MS analysis may be necessary to facilitate sequencing and identification of post-translational modifications (PTMs). The accurate intact mass and MS/MS spectrum of the peptide species is obtained from the initial LC-MS/MS data collection. If necessary, further characterization is carried out utilizing the library fraction containing the most abundant amount of the peptide species of interest. Reduction and alkylation of cysteine residues is used to determine the number of disulfide bonds. Proteolysis is used to assess disulfide bond connectivity and possible cyclizations (e.g., cyclotides containing a single glutamic acid residue can be linearized through cleavage with endoproteinase GluC<sup>32</sup>). Paired Lys-C and Lys-N digestions can facilitate determination of termini by allowing identification with high confidence of *b*- and *y*-ions from the isobaric precursor ions.<sup>33</sup> Complementary tandem MS fragmentation via CID and ECD/ETD is used in combination to maximize peptide primary sequence determination and post-translational modification localization.<sup>31,34,35</sup> *De novo* peptide sequencing will be facilitated using PEAKS software (Bioinformatics Solutions, Inc.),<sup>36</sup> supplemented with composition-based sequencing<sup>37,38</sup> and homology-based database searches<sup>39</sup> to address plant species with limited sequencing information available. Structural mapping to delineate disulfide bond connectivity is carried out in combination with multienzyme digestions,<sup>35</sup> as appropriate, to dissect these key features that often confer bioactivity.


**Isolation and *In Vitro/In Vivo* Validation of Prioritized Bioactive Peptides.** Bioactive peptides that have been characterized are validated and their requisite bioactivity characterized. *In vivo* confirmation/validation of a bioactive peptide requires isolation to a high degree of purity to allow testing without interference from contaminating coeluting compounds. Split-flow UPLC-MS or *de novo* synthesis of peptides will permit necessary biological and pharmacological testing to determine if a peptide is a satisfactory lead compound that should be further evaluated.

**Platform Validation.** To validate the PepSAVI-MS pipeline, we demonstrate successful detection and identification of a known AMP from the botanical species *Viola odorata*. *Viola odorata*, which is commonly known as sweet violet, contains many cyclotides,<sup>40</sup> including cycloviolacin O2 (cyO2). cyO2 is a small, cysteine-rich cyclotide comprised of 30 amino acids (MW<sub>monoisotopic</sub>: 3138.37 Da), which has been shown to have diverse activity against many Gram-negative bacteria (*E. coli*, *K. pneumoniae*, and *P. aeruginosa*),<sup>41</sup> as well as several cancer cell lines.<sup>42,43</sup> Following the PepSAVI-MS pipeline as described above, *V. odorata* plants were grown, harvested, extracted, and crudely fractionated for creation of its peptide library. Using the known activities of cyO2 as a guide for assay selection, antibacterial bioassays were performed against *E. coli* (Figure 2a) and a panel of clinical strains representing the ESKAPE pathogens<sup>17</sup> (Figure 4 and Figure S-2 in the Supporting Information). Each bioassay yielded robust bioactivity profiles unique to each microbe tested. Fractions containing the mass corresponding to cyO2 demonstrated growth inhibition for *A.*



**Figure 2.** *V. odorata* fractions (a) bioactivity vs *Escherichia coli* with the growth-inhibition defined bioactivity region in blue, where “% activity” indicates the decrease in bacterial aerobic metabolism quantified by resazurin reduction. (b) Aligned cyO2 elution profile with comparison of manual (yellow) and automated (gray) extraction of the detected cyO2 charge states.

*baumannii*, *P. aeruginosa*, and *E. coli*, but not for *E. faecium*, *S. aureus*, *K. pneumoniae*, or *E. cloacae*. As demonstrated previously,<sup>44</sup> the crude nature of SCX separation often results in group isolation of cyclotides (Figure S-3 in the Supporting Information). Hence, these fractions also contained additional cyclotides that have the potential to contribute to the aforementioned activity. The majority of the remaining fractions did not show growth inhibition, indicating that the source of activity was due to constituents within the fractions, rather than the extract itself. To further demonstrate the broad applicability of the platform, *V. odorata* fractions were screened for activity against human breast (MDA-MB-231), prostate (PC3), and ovarian (OVCAR) carcinoma cell lines and yielded robust activity profiles with increased cytotoxicity for these neoplastic cells, in comparison to a noncancerous human dermal fibroblast cell line (Figure 3). *Viola odorata* peptide library was also screened for growth inhibition against the filamentous fungus, *Fusarium graminearum* (PH-1), which similarly yielded a robust activity profile across the cyclotide-containing fractions (Figure S-4 in the Supporting Information). To determine which of the detected cyclotides could be contributing to the aforementioned bioactivity, the *V. odorata* peptide library was subjected to LC-MS/MS and statistical analysis with the developed PepSAVI-MS software package. Retention time alignment and peak-picking of detected ions identified 6258 unique features across *V. odorata* fractions 11–43. To validate our automated workflow for data processing, extracted ion chromatograms of cyO2 peptide were plotted for manual versus automated data extraction (Figure 2b). Extracted ion chromatograms show that cyO2 was detected at varying abundances across fractions 18–22 and validate the use of automation for data array generation. Following the known mass and charge properties of bioactive peptides, exported peptide ion data was filtered to include masses between 2 and 15 kDa having charge states between +2 and +9 and eluting between 14 and 45 min. Remaining data were then binning




**Figure 3.** *Viola odorata* peptide library bioactivity profile against (a) breast (MDA-MB-231), (b) ovarian (OVCAR), and (c) prostate (PC3) cancer cell lines, and (d) a noncancerous human dermal fibroblast cell line. The cytotoxicity-defined bioactivity region of cyO2 against the given cell line is defined with blue bars for cancer cell lines and yellow bars for the noncancerous cell line.

using a 0.05 Da mass window with identical charge state requirements. Using the workflow informed criteria (described above) for data filtering and reduction with the bioactivity region specified as fractions 17–25, the number of possible candidates contributing to bioactivity was reduced to 225. This resulting list of candidate peptides was then subjected to statistical modeling of all bioactivity datasets, using the sparse penalized regression method, elastic net.<sup>28</sup> cyO2 from *V. odorata* was within the top 20 candidates for 2 of the 7 active species when modeled against the averaged bioactivity data. Furthermore, modeling individual bioactivity replicates with the requirement that any true component must be pulled out in at least two of the three replicates can further reduce the number of considered compounds for each dataset. CyO2 was characterized via a multistep mass spectrometry-based approach (Figure S-5 in the Supporting Information), and these results are in agreement with previously published findings, thus confirming the identity of cyO2.<sup>40,45</sup> MS<sup>2</sup> sequence coverage across the peptide allowed for distinction from another cyclotide, cyO9, that was present in sweet violet with the same intact mass as cyO2, differing only by three residues. Only one other cyclotide corresponding to the intact mass of cyO17 appeared in the top 20 candidates after data reduction and statistical modeling of the *E. coli* bioactivity dataset. No other known cyclotides appeared in the top 20 candidates for any of the other bioactivity datasets. While this does not eliminate the possibility that other cyclotides could be contributing to the activity, our experiments suggest that cyO2 was the main contributor. To allow for greater access to the scientific community, the statistical analysis methods established for this platform have been developed into an R package, PepSAVIm, that is publicly available through CRAN (<https://cran.r-project.org/package=PepSAVIm>). Included with this package are two vignettes, which provide an in-depth description of the functionality of the PepSAVI-MS pipeline package, as well as the specific bioinformatics implementation performed in this manuscript.

To confirm that these bioassays are capable of detecting AMP activity at concentrations relevant for the observed activity, the minimum inhibitory concentration (MIC) of isolated cyO2 against *E. coli* was determined. Using a broth

microdilution assay in 96-well plate format, the MIC was determined to be 5  $\mu$ M, which lies between the previously reported MIC of 2.2  $\mu$ M<sup>41</sup> and IC<sub>50</sub> of 6.8  $\mu$ M<sup>13</sup> for the same peptide on *E. coli* using different protocols. The concentration of cyO2 in the most abundant fraction (21) that killed or inhibited these strains was determined to be  $\sim$ 300  $\mu$ M via area-under-the-curve integration of RPLC-MS peaks, which is in excess of the MIC needed for growth inhibition.

**Novel Findings.** In addition to platform validation, unknown activities of cyO2 from *V. odorata* have been revealed in this study. Previously, it was demonstrated that cyO2 was active against a subset of the ESKAPE pathogens, including *K. pneumoniae*, and *P. aeruginosa*, and inactive against the tested Gram-positive bacteria, including *S. aureus* and *E. faecium*.<sup>41</sup> Results from our study are in agreement with the activity of cyO2 in the cyclotide fractions against *E. coli* and *P. aeruginosa*, and inactivity against *E. faecium* and *S. aureus*. However, we could not detect activity in these fractions against *K. pneumoniae*, which could be influenced by the high strain variability among this bacterial species.<sup>46,47</sup> In addition, our assay detects strong activity of the cyclotide fractions against *A. baumannii*, of which there are no known reported studies of activity (Figure 4). The MIC for the ESKAPE pathogen



**Figure 4.** Bioactivity data representing the novel activity of *Viola odorata* fractions versus the ESKAPE pathogen *Acinetobacter baumannii*. The growth inhibition-defined bioactivity region of cyO2 is depicted in blue.

representing novel activity, *A. baumannii*, was determined to be 15  $\mu$ M, using isolated cyO2, and thus supports that cyO2 is the main contributor to the activity seen in these fractions. Throughout this study, we have noticed variation in the sensitivity of peptidyl activity, because of differences in media conditions and salt concentrations (Figure S-6 in the Supporting Information). We suspect that small differences, even within different brands of the same medium, could cause inaccurate assessment of bioactivity,<sup>48,49</sup> necessitating validation of new lots of media through testing of established fraction libraries to confirm consistency with previously collected bioactivity data. While our study shows some examples of changes in activity due to strain variability, the majority of findings remain consistent across different strains of the same species.

Screening of *V. odorata* fractions against a panel of human cancer cell lines similarly demonstrates a proof-of-principle, as well as an additional novel finding. In previous studies, cyO2



has been shown to have anticancer activity against multiple breast and ovarian cancer cell lines.<sup>42,43</sup> Although our screen used different cell lines, strong activity was observed against the MDA-MB-231 breast cancer cell line, as well as the OVCAR ovarian cancer cell line across fractions in which cyO2 was eluted. In addition, this is the first demonstration of the ability of purified cyO2 to kill PC3 prostate cancer cells, with a determined IC<sub>50</sub> of 6.6  $\mu\text{g/mL}$  (2.1  $\mu\text{M}$ ). Furthermore, we demonstrate that the cyclotide fractions can kill the filamentous fungus *F. graminearum* and suspect the presence of an additional peptide(s) from *V. odorata* possessing antifungal capabilities (fractions 28–36). These studies not only highlight the wide applicability of this platform but also the capabilities of antimicrobial peptides as broad-spectrum therapeutics.

## CONCLUSIONS

As demonstrated herein, the developed PepSAVI-MS pipeline involves broad spectrum and high throughput, and it has the potential to expedite the search for new bioactive peptides from plants. Our platform overcomes many traditional limitations of drug discovery efforts through achieving increased efficiency by directly targeting and characterizing only those species contributing to the bioactivity. This may eliminate many laborious rounds of bioassay-guided fractionation or the need for characterization of all molecular species present, regardless of demonstrated activity. Furthermore, the developed platform is highly versatile, since it is adaptable to any natural product source of peptides and can test against diverse physiological targets, including bacteria, fungi, viruses, protozoans, and cancer cells for which there is a developed bioassay. With this platform, there is little bias toward high-abundance compounds, since the trend of activity values is more important than the raw abundance values. While the PepSAVI-MS pipeline has been developed to target cationic AMPs, the platform is adaptable to target other types of compounds by changing the type of chromatography performed. The PepSAVI-MS pipeline opens the door for investigating purpose-guided natural product extracts with a new lens, and has the potential to lead to the discovery of novel chemistries at the forefront of modern drug discovery.

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.analchem.6b03625.

Additional figures depicting SCX fractionation of *V. odorata* (Figure S-1), bioactivity screening of the *V. odorata* library versus the remaining ESKAPE pathogens (Figure S-2), and *F. graminearum* (Figure S-4), SCX elution profiles of other detected cyclotides (Figure S-3), mass spectral characterization of cyO2 (Figure S-5), and different media effects on the observed bioactivity profiles (Figure S-6) (PDF)

## AUTHOR INFORMATION

### Corresponding Author

\*Postal Address: 125 South Rd., CB#3290, Chapel Hill, NC 27599, USA. Tel.: 919-843-6903. Fax: 919-962-2388. E-mail: lmhicks@unc.edu.

### ORCID

Adam A. Strömstedt: 0000-0001-9070-6944

Lindsey N. Shaw: 0000-0002-0629-8990

Leslie M. Hicks: 0000-0002-8008-3998

## Author Contributions

C.L.K., A.J., D.W.H., L.N.S., and L.M.H. designed research; C.L.K., C.A.B., E.N.M., W.J.L., M.H., R.F., J.A., L.M., and A.A.S. performed research; C.L.K., A.C., E.W.M., D.A.P., and Y.L. analyzed data; C.L.K., C.A.B., A.A.S., Y.L., U.G., D.W.H., L.N.S., and L.M.H. wrote the paper.

## Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

We acknowledge the Pakistan-U.S. Science and Technology Cooperation Program (Phase 4 funding to L.M.H. and A.J.) and Awais Altaf, Brian Gau, Nazia Kanwal, Brian Kelly, Sumaira Kousar, Alicia Malone, and William Slade for financial and technical assistance, respectively, in the preliminary development of the PepSAVI-MS pipeline.

## REFERENCES

- (1) Klevens, R. M.; Edwards, J. R.; Richards, C. L., Jr.; Horan, T. C.; Gaynes, R. P.; Pollock, D. A.; Cardo, D. M. *Public Health Rep.* **2007**, *122*, 160–166.
- (2) Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. *Clin. Infect. Dis.* **2009**, *48*, 1–12.
- (3) Howard, C. R.; Fletcher, N. F. *Emerging Microbes Infect.* **2012**, *1*, e46.
- (4) Guzman-Rodriguez, J. J.; Ochoa-Zarzosa, A.; Lopez-Gomez, R.; Lopez-Meza, J. E. *BioMed Res. Int.* **2015**, *2015*, 735087.
- (5) Harvey, A. L.; Edrada-Ebel, R.; Quinn, R. J. *Nat. Rev. Drug Discovery* **2015**, *14*, 111–129.
- (6) Arnison, P. G.; Bibb, M. J.; Bierbaum, G.; Bowers, A. A.; Bugni, T. S.; Bulaj, G.; Camarero, J. A.; Campopiano, D. J.; Challis, G. L.; Clardy, J.; Cotter, P. D.; Craik, D. J.; Dawson, M.; Dittmann, E.; Donadio, S.; Dorrestein, P. C.; Entian, K. D.; Fischbach, M. A.; Garavelli, J. S.; Göransson, U.; Gruber, C. W.; Haft, D. H.; Hemscheidt, T. K.; Hertweck, C.; Hill, C.; Horswill, A. R.; Jaspars, M.; Kelly, W. L.; Klinman, J. P.; Kuipers, O. P.; Link, A. J.; Liu, W.; Marahiel, M. A.; Mitchell, D. A.; Moll, G. N.; Moore, B. S.; Muller, R.; Nair, S. K.; Nes, I. F.; Norris, G. E.; Olivera, B. M.; Onaka, H.; Patchett, M. L.; Piel, J.; Reaney, M. J.; Rebuffat, S.; Ross, R. P.; Sahl, H. G.; Schmidt, E. W.; Selsted, M. E.; Severinov, K.; Shen, B.; Sivonen, K.; Smith, L.; Stein, T.; Sussmuth, R. D.; Tagg, J. R.; Tang, G. L.; Truman, A. W.; Vederas, J. C.; Walsh, C. T.; Walton, J. D.; Wenzel, S. C.; Willey, J. M.; van der Donk, W. A. *Nat. Prod. Rep.* **2013**, *30*, 108–160.
- (7) Essig, A.; Hofmann, D.; Munch, D.; Gayathri, S.; Kunzler, M.; Kallio, P. T.; Sahl, H. G.; Wider, G.; Schneider, T.; Aebi, M. *J. Biol. Chem.* **2014**, *289*, 34953–34964.
- (8) Schweizer, F. *Eur. J. Pharmacol.* **2009**, *625*, 190–194.
- (9) Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatsky, M. *Drug Discovery Today* **2010**, *15*, 40–56.
- (10) Mandal, S. M.; Roy, A.; Ghosh, A. K.; Hazra, T. K.; Basak, A.; Franco, O. L. *Front. Pharmacol.* **2014**, *5*, 105.
- (11) Walensky, L. D.; Bird, G. H. *J. Med. Chem.* **2014**, *57*, 6275.
- (12) Mohimani, H.; Kersten, R. D.; Liu, W. T.; Wang, M.; Purvine, S. O.; Wu, S.; Brewer, H. M.; Pasa-Tolic, L.; Bandeira, N.; Moore, B. S.; Pevzner, P. A.; Dorrestein, P. C. *ACS Chem. Biol.* **2014**, *9*, 1545–1551.
- (13) Henriques, S. T.; Huang, Y. H.; Castanho, M. A.; Bagatolli, L. A.; Sonza, S.; Tachedjian, G.; Daly, N. L.; Craik, D. J. *J. Biol. Chem.* **2012**, *287*, 33629–33643.
- (14) Medema, M. H.; Paalvast, Y.; Nguyen, D. D.; Melnik, A.; Dorrestein, P. C.; Takano, E.; Breitling, R. *PLoS Comput. Biol.* **2014**, *10*, e1003822.

- (15) Skinnider, M. A.; Johnston, C. W.; Edgar, R. E.; Dejong, C. A.; Merwin, N. J.; Rees, P. N.; Magarvey, N. A. *Proc. Natl. Acad. Sci. U. S. A.* **2016**, *113*, E6343–e6351.
- (16) Kurita, K. L.; Glassey, E.; Linington, R. G. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112*, 11999–12004.
- (17) Fleeman, R.; LaVoi, T. M.; Santos, R. G.; Morales, A.; Nefzi, A.; Welmaker, G. S.; Medina-Franco, J. L.; Giulianotti, M. A.; Houghten, R. A.; Shaw, L. N. *J. Med. Chem.* **2015**, *58*, 3340–3355.
- (18) Vizcaino, J. A.; Csordas, A.; del-Toro, N.; Dianes, J. A.; Griss, J.; Lavidas, I.; Mayer, G.; Perez-Riverol, Y.; Reisinger, F.; Ternent, T.; Xu, Q. W.; Wang, R.; Hermjakob, H. *Nucleic Acids Res.* **2016**, *44*, D447–456.
- (19) Herrmann, A.; Burman, R.; Mylne, J. S.; Karlsson, G.; Gullbo, J.; Craik, D. J.; Clark, R. J.; Göransson, U. *Phytochemistry* **2008**, *69*, 939–952.
- (20) Hammami, R.; Ben Hamida, J.; Vergoten, G.; Fliss, I. *Nucleic Acids Res.* **2009**, *37*, D963–968.
- (21) Adochite, R. C.; Moshnikova, A.; Carlin, S. D.; Guerrieri, R. A.; Andreev, O. A.; Lewis, J. S.; Reshetnyak, Y. K. *Mol. Pharmaceutics* **2014**, *11*, 2896–2905.
- (22) Garcia-Olmedo, F.; Molina, A.; Alamillo, J. M.; Rodriguez-Palenzuela, P. *Biopolymers* **1998**, *47*, 479–491.
- (23) Epple, P.; Apel, K.; Bohlmann, H. *Plant Physiol.* **1995**, *109*, 813–820.
- (24) Lee, S. C.; Hwang, B. K. *Plant Mol. Biol.* **2006**, *61*, 95–109.
- (25) van Loon, L. C.; Rep, M.; Pieterse, C. M. *Annu. Rev. Phytopathol.* **2006**, *44*, 135–162.
- (26) Sarker, S. D.; Nahar, L.; Kumarasamy, Y. *Methods* **2007**, *42*, 321–324.
- (27) Zou, H.; Hastie, T. *J. R. Stat. Soc.: Ser. B (Stat. Methodol.)* **2005**, *67*, 301–320.
- (28) Zou, H.; Hastie, T. *elasticnet: Elastic-Net for Sparse Estimation and Sparse PCA* (<http://CRAN.R-project.org/package=elasticnet>), 2012.
- (29) Tibshirani, R. *J. R. Stat. Soc.: Ser. B (Stat. Methodol.)* **1996**, *58*, 267–288.
- (30) Efron, B.; Hastie, T.; Johnstone, I.; Tibshirani, R. *Ann. Statist.* **2004**, *32*, 407–499.
- (31) Guerrero, A.; Lerno, L.; Barile, D.; Lebrilla, C. B. *J. Am. Soc. Mass Spectrom.* **2015**, *26*, 453–459.
- (32) Poth, A. G.; Colgrave, M. L.; Philip, R.; Kerenga, B.; Daly, N. L.; Anderson, M. A.; Craik, D. J. *ACS Chem. Biol.* **2011**, *6*, 345–355.
- (33) Brownstein, N. C.; Guan, X.; Mao, Y.; Zhang, Q.; DiMaggio, P. A.; Xia, Q.; Zhang, L.; Marshall, A. G.; Young, N. L. *Rapid Commun. Mass Spectrom.* **2015**, *29*, 659–666.
- (34) Hayakawa, E.; Menschaert, G.; De Bock, P.-J.; Luyten, W.; Gevaert, K.; Baggerman, G.; Schoofs, L. *J. Proteome Res.* **2013**, *12*, 5410–5421.
- (35) Ni, W.; Lin, M.; Salinas, P.; Savickas, P.; Wu, S. L.; Karger, B. L. *J. Am. Soc. Mass Spectrom.* **2013**, *24*, 125–133.
- (36) Ma, B.; Zhang, K.; Hendrie, C.; Liang, C.; Li, M.; Doherty-Kirby, A.; Lajoie, G. *Rapid Commun. Mass Spectrom.* **2003**, *17*, 2337–2342.
- (37) Spengler, B. *J. Am. Soc. Mass Spectrom.* **2004**, *15*, 703–714.
- (38) Langsdorf, M.; Ghassempour, A.; Rompp, A.; Spengler, B. *Rapid Commun. Mass Spectrom.* **2010**, *24*, 2885–2899.
- (39) Ma, B.; Johnson, R. *Mol. Cell. Proteomics* **2012**, *11*, Manuscript O111.01490210.1074/mcp.O111.014902.
- (40) Ireland, D. C.; Colgrave, M. L.; Craik, D. J. *Biochem. J.* **2006**, *400*, 1–12.
- (41) Prätting, M.; Lööv, C.; Burman, R.; Göransson, U.; Andersson, D. I. *J. Antimicrob. Chemother.* **2010**, *65*, 1964–1971.
- (42) Gerlach, S. L.; Rathinakumar, R.; Chakravarty, G.; Göransson, U.; Wimley, W. C.; Darwin, S. P.; Mondal, D. *Biopolymers* **2010**, *94*, 617–625.
- (43) Lindholm, P.; Göransson, U.; Johansson, S.; Claeson, P.; Gullbo, J.; Larsson, R.; Bohlin, L.; Backlund, A. *Mol. Cancer Ther.* **2002**, *1*, 365–369.
- (44) Göransson, U.; Sjogren, M.; Svargard, E.; Claeson, P.; Bohlin, L. *J. Nat. Prod.* **2004**, *67*, 1287–1290.
- (45) Göransson, U.; Herrmann, A.; Burman, R.; Haugaard-Jönsson, L. M.; Rosengren, K. J. *ChemBioChem* **2009**, *10*, 2354–2360.
- (46) Lai, Y. C.; Yang, S. L.; Peng, H. L.; Chang, H. Y. *Infect. Immun.* **2000**, *68*, 7149–7151.
- (47) Wu, K. M.; Li, L. H.; Yan, J. J.; Tsao, N.; Liao, T. L.; Tsai, H. C.; Fung, C. P.; Chen, H. J.; Liu, Y. M.; Wang, J. T.; Fang, C. T.; Chang, S. C.; Shu, H. Y.; Liu, T. T.; Chen, Y. T.; Shiau, Y. R.; Lauderdale, T. L.; Su, I. J.; Kirby, R.; Tsai, S. F. *J. Bacteriol.* **2009**, *191*, 4492–4501.
- (48) Park, I. Y.; Cho, J. H.; Kim, K. S.; Kim, Y. B.; Kim, M. S.; Kim, S. C. *J. Biol. Chem.* **2004**, *279*, 13896–13901.
- (49) Schwab, U.; Gilligan, P.; Jaynes, J.; Henke, D. *Antimicrob. Agents Chemother.* **1999**, *43*, 1435–1440.